Roche Pharma announced plans to invest a minimum of 1.5 billion Swiss francs in India over the next five years, underscoring its long-term commitment to the country’s healthcare and pharmaceutical sector.
Strategic Announcement at EFTA Summit
The announcement was made by Francois du Toit, Area Head for CEETRIS (Central Eastern Europe, Turkiye, Russia, and Indian Subcontinent), during the India-European Free Trade Association (EFTA) Prosperity Summit. The move coincides with the implementation of India’s free trade agreement with the EFTA bloc, reflecting Roche’s intent to strengthen ties and expand its footprint in the region.
Investment Focus: R&D and Healthcare Collaboration
Roche, plans to channel the investment into three strategic areas, with a strong emphasis on research and development (R&D). Additionally, the company aims to collaborate with flagship healthcare initiatives, including Ayushman Bharat, to expand access to innovative medicines and healthcare solutions for a broader patient base.
Supporting India’s Growing Pharma and Innovation Ecosystem
The investment aligns with India’s emergence as both a major pharmaceutical market and a hub for medical innovation. Projectstoday.com reports that Roche will enhance patient access, drive innovation, and contribute to India’s healthcare sector by strengthening R&D and partnering with national healthcare programs.
